Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system

Annals of Clinical and Laboratory Science

Volumn 28, Issue 2, 1998, Pages 67-81

  Fosslien, Egil ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 FLUOROPHENYL) 2 [(4 METHYLSULFONYL)PHENYL]CYCLOPENTENE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE; ARACHIDONIC ACID; BENZO[A]PYRENE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ENDOTOXIN; EPIDERMAL GROWTH FACTOR; FLOSULIDE; FLURBIPROFEN; INDOMETACIN; INTERLEUKIN 1; LEUKOTRIENE; LIPOXYGENASE INHIBITOR; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN; SALICYLATE SODIUM; SULINDAC; TEPOXALIN; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG; ZILEUTON;

ARTICLE; CELL PROTECTION; GASTROINTESTINAL TOXICITY; HUMAN; INTESTINE MUCOSA; NEUTROPHIL; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TIGHT JUNCTION; VASOCONSTRICTION;

AGING; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; LIPOXYGENASE INHIBITORS; MALE;

EID: 0031960403     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (111)

1. Garcia J, Altman RD. Chronic pain states: pathophysiology and medical therapy. Semin Arthritis Rheum 1997;27:1-16.
2. Amadio P. NSAIDs revisited. Selection, monitoring, and safe use. Postgrad Med 1997;101:257-76.
3. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991;91:213-22.
4. Siebert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, Isakson P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994;91:12013-17.
5. Brigden M, Smith RE. Acetylsalicylic-acid-containing drugs and nonsteroidal anti-inflammatory drugs available in Canada. Can Med Assoc J 1997;156: 1025-8.
6. Hawkey CJ. Gastroduodenal problems associated with non-steroidal, anti-inflammatory drugs (NSAIDs). Scand J Gastroenterol Suppl 1993;200: 94-5.
7. Urquhart E. Analgesic agents and strategies in the dental pain model. J Dent 1994;22:336-41.
8. Cashman J, McAnulty G. Nonsteroidal anti-inflammatory drugs in perisurgical pain management. Mechanism of action and rationale for optimum use. Drugs 1995;49:51-70.
9. Montalescot G. [Use of aspirin in coronary disease]. Presse Med 1995;24:925-7.
10. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
11. Giardiello FM. NSAID-induced polyp regression in familial adenomatous polyposis patients. Gastroenterol Clin North Am 1996;25:349-62.
12. Gustafson-Svärd C, Lilja I, Hallböök O, Sjödahl R. Cyclo-oxygenase and colon cancer: clues to the aspirin effect? Ann Med 1997;29:247-52.
13. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI, Rigas B. Effects on nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52:237-45.
14. Breitner JC. Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Proc Natl Acad Sci USA. 1996;93:11091-6.
15. Polisson R. Nonsteroidal anti-inflammatory drugs: Practical and the theoretical considerations in their selection. AJM 1996;100:Suppl 31S-6S.
16. Colin R. Digestive complication of non-steroid antiinflammatory drugs. Schweiz Med Wochenschr 1991;121:716-21.
17. Mohamed AH, Salena BH, Hunt RH. NSAID-induced gastroduodenal ulcers: exploring the silent dilemma. J Gastroenterol 1994;29:Suppl 7:34-8.
18. Hawkey CJ. Non-steroidal anti-inflammatory drug gastropathy: causes and treatment. Scand J Gastroenterol 1994;29:Suppl 220 M:124-7.
19. Peltier AP. Practical management of NSAID gastropathy in rheumatic patients. Scand J Rheumatol Suppl 1989;78:12-7.
20. Blower AL. Consideration for nonsteroidal antiinflammatory drug therapy: safety. Scand J Rheumatol 1996;105:Suppl 13-24.
21. Carson JL, Willett LR. Toxicity of nonsteroidal antiinflammatory drugs. An overview of the epidemiological evidence. Drugs 1993;46:Suppl 1:243-8.
22. Miwa LJ, Jones JK, Pathiyal A, Hatoum H. Value of epidemiologic studies in determining the true incidence of adverse events. The nonsteroidal antiinflammatory drug story. Arch Intern Med 1997;157: 2129-36.
23. Hawkey CJ, Cullen DJ, Greenwood DC, Wilson JV, Logan RF. Prescribing of nonsteroidal antiinflammatory drugs in general practice: determinants and consequences. Aliment Pharmacol Ther 1997;11:293-8.
24. Wilcox CM, Alexander LN, Cotsonis GA, Clark WS. Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding. Dig Dis Sci 1997;42:990-7.
25. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996;6: 489-504.
26. Svanes C, Överebo K, Söreide O. Ulcer bleeding and perforation: non-steroid anti-inflammatory drugs or Helicobacter pylori. Scand J Gastroenterol 1996;Suppl 220:128-31.
27. Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997;112:683-9.
28. Bar Dayan Y, Amital H, Levy Y, Shoenfeld Y. Low dose aspirin in patients with ischemic heart disease may precipitate secondary myocardial infarction. Isr J Med Sci 1996;32:288-91.
29. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. Identification of patients at risk for gastropathy associated with NSAID use. J Rheumatol 1990;20(Suppl):12-9.
30. Wolfe MM. NSAIDs and the gastrointestinal mucosa. Hosp Ptract 1996Dec 15;31:37-44.
31. Hayllar J, Macpherson A, Bjamason I. Gastroprotection and nonsteroidal anti-inflammatory drugs (NSAIDs). Rationale and clinical implications. Drug Saf 1992;7:86-105.
32. Blower AL, Brooks A, Fenn GC, Hill A, Pearce MY, Morant S, Bardhan KD. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997;11:283-91.
33. Aly A. NSAID-induced ulcer and its complications. Nord Med 1997;112:195-7.
34. Kurata JH, Nogawa AN, Noritake D. NSAIDs increase risk of gastrointestinal bleeding in primary care patients with dyspepsia. J Fam Pract 1997;45:227-35.
35. Bertschinger P, Zala GF, Fried M. Effect of nonsteroidal antirheumatic agents on the gastrointestinal tract: clinical aspects and pathophysiology. Schweiz Med Wochenschr 1996;126:1566-8.
36. Roth SH. From peptic ulcer disease to NSAID gastropathy. An evolving nosology. Drugs Aging 1995; 6:358-67.
37. Guttmann SP, Garcia Rodriguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997;8:18-24.
38. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
39. Davies NM. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Dis Colon Rectum 1995;38:1311-21.
40. Bjarnason I, Macpherson A. The changing gastrointestinal side effect profile of non-steroidal antiinflammatory drugs. A new approach for the prevention of a new problem. Scand J Gastroenterol Suppl 1989;163:56-64.
41. El-Serag HB, Sonnenberg A. Association of esophagitis and esophageal strictures with diseases treated with nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 1997;92:52-6.
42. Hayllar J, Smith T, Macpherson A, Price AB, Gumpel M, Bjarnason I. Nonsteroidal antiinflammatory drug-induced small intestinal inflammation and blood loss. Arthrit Rheumat 1994;37:1146-50.
43. Lesur G. Non-gastroduodenal digestive toxicity of non-steroidal anti-inflammatory agents. Presse Med 1996;25:1376-80.
44. Davies NM, Wright MR, Fussel AS, Jamali F. Effect of the enantiomers of flurbiprofen, ibuprofen, and ketoprofen on intestinal permeability. J Pharm Sci 1996;85:1170-3.
45. Carratu R, Parisis P, Agozzino A. Segmental ischemic colitis associated with nonsteroidal antiinflammatory drugs. J Clin Gastroenterol 1993;16:31-4.
46. Cashman JN. The mechanism of action of NSAIDs in analgesia. Drugs 1996;52 Suppl 5:13-23.
47. Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: new insight into an old problem. J Gastroenterol 1997;32: 127-33.
48. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971;231:232-5.
49. Vane JR, Botting RM. Mechanism of action of aspirin-like drugs. Semin Arthritis Rheum 1997;26(6 Suppl 1):2-10.
50. Jouzeau JY, Terlain B, Abid A, Nedelec E, Netter P. Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 1997;53:563-82.
51. Ferraz JG, Wallace JL, McKnight W, Brown ML. Induction of cyclooxygenase 1 and 2 in the rat stomac during endotoxemia: role in resistance to damage. Gastroenterology 1997;113:195-204.
52. Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, Dannenberg AJ. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996;56: 4424-9.
53. Zhang Y, Shaffer A, Portanova J, Seibert K, Isakson PC. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther 1997;28:1069-75.
54. Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 1997;112:109-17.
55. Sato N, Kawano S, Tsuji S, Ogihara T, Yamada S. Gastric blood flow in ulcer diseases. Scand J Gastroenterol Suppl 1995;208:14-20.
56. Banos G, Reyes PA. A comparative study of the effect of ten non-steroid anti-inflammatory drugs (NSAIDs) upon some mitochondrial and platelet functions. Int J Biochem 1989;21:1387-94.
57. Mahmud T, Wrigglesworth JM, Rafi S, Scott DL, Bjarnason I. Uncoupling of oxidative phosphorylation by non-steroidal anti-inflammatory drugs (NSAIDs) is related to ionizable moiety and can be altered by modification of carboxylic group. Arthritis Rheum 1995;38 (Suppl):S207.
58. Simon LS. Biologic effects of nonsteroidal antiinflammatory drugs. Curr Opin Rheumatol 1997;9: 178-82.
59. Mingatto FE, Santos AC, Uyemura SA, Jordani MC, Curti C. In vitro interaction of nonsteroidal antiinflammatory drugs on oxidative phosphorylation of rat kidney mitochondria: respiration and ATP synthesis. Arch Biochem Biophys 1996;334:303-8.
60. Somasundaram S, Rafi S, Hayllar J, Sigthorsson G, Jacob M, Price AB, Macpherson A, Mahmod T, Scott D, Wrigglesworth JM, Bjarnason I. Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine. Gut 1997;41:344-53.
61. Bjarnason I, Smethurst P, Fenn CG, Lee CE, Menzies IS, Levi AJ. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci 1989;34:407-11.
62. Mahmud T, Scott DL, Bjarnason I. A unifying hypothesis for the mechanism of NSAID-related gastrointestinal toxicity. Ann Rheum Dis 1996;55:211-3.
63. Wallace JL. Prostaglandins, NSAIDs, and cytoprotection. Gastroenterol Clin North Am 1992;21:631-41.
64. Kirchner T, Aparicio B, Artentieri DC, Lau CY, Ritchie DM. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins Leukot Essent Fatty Acids 1997;56: 417-23.
65. Shah K, Price AB, Talbot IC, Bardhan KD, Fenn CG, Bjarnason I. Effect of long-term misoprostol coadministration with non-steroidal antiinflammatory drugs: a histological study. Gut 1995; 37:195-8.
66. Raskin JB, White RH, Jaszewski R, Korsten MA, Schubert TT, Fort JG. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective double-blind, multicenter study. Am J Gastroenterol 1996;91:223-7.
67. Langebach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995;83:483-92.
68. Morgan G. NSAID treatment of gastrointestinal abnormalities: A challenge to 'cytoprotection'. Scand J Gastroenterol 1997;32:288.
69. Crofford LJ, Tan B, McCarthy CJ, Hla T. Involvement of nuclear factor kappa b in the regulation of cyclooxygenase-2-expression by interleukin-1 in rheumatoid synoviocytes. Arthritis Rheum 1997;40: 2226-36.
70. Schmedtje JF Jr, Ji YS, Liu WL, DuBois RN, Runge MS. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 1997;272:601-8.
71. Perkins DJ, Kniss DA. Rapid and transient induction of cyclo-oxygenase 2 by epidermal growth factor in human amino-derived WISH cells. Biochem J 1997;321(Pt 3):677-81.
72. Kelley DJ, Mestr JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, Ramonerti JT, Dannenberg AJ. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis 1997;18:795-9.
73. Sheng H, Shao J, Hooton EB, Tsujii M, DuBois, Beauchamp RD. Cyclooxygenase-2 induction and transforming growth factor beta growth inhibition in rat intestinal epithelial cells. Cell Growth Differ 1997;8:463-70.
74. Wallace AD, Wheeler TT, Young DA. Inducibility of E4BP4 suggests a novel mechanism of negative gene regulation by glucocorticoids. Biochem Biophys Res Commun 1997;232:403-6.
75. Katori M, Majima M: [Multiple roles of inducible cyclooxygenase-2 and its selective inhibitors]. Nippon Yakurigaku Zasshi 1997;109:247-58.
76. Morham SG, Langebach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette C. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995;83:473-82.
77. Kirchner T, Aparicio B, Artentieri DC, Lau CY, Ritchie DM. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins Leukot Essent Fatty Acids 1997;56: 417-23.
78. Rainsford KD. Mechanisms of gastrointestinal toxicity of non-steroid anti-inflammatory drugs. Scand J Gastroenterol Suppl 1989;163:9-16.
79. Wallace JL. Gastric ulceration: critical events at the neutrophil-endothelium interface. Can J Physiol Pharmacol 1993;71:98-102.
80. Rainsford KD. Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal mucosal damage. Agents Actions 1993;39:C24-6.
81. Scheiman JM, Tillner A, Phol T, Oldenburg A, Angermuller S, Gorlach E, Engel G, Usadel KH, Kusterer K. Reduction of non-steroidal antiinflammatory drug induced gastric injury and leucocyte endothelial adhesion by octreotide. Gut 1997; 40:720-5.
82. Cronstein BN, Van de Stouwe M, Druska L, Levin RI, Weissmann G. Nonsteroidal antiinflammatory agents inhibit stimulated neutrophil adhesion to endothelium: adenosine dependent and independent mechanisms. Inflammation 1994;18:323-35.
83. Fiorucci S, Santucci L, Gerli R, Brunori PM, Federici B, Ugolini B, Fabbri C, Morelli A. NSAIDs upregulate beta 2-integrin expression on human neutrophils through a calcium-dependent pathway. Aliment Pharmacol Ther 1997;11:619-30.
84. Kishi K, Kinoshita Y, Matushima Y, Okada A, Maekawa T, Kawanami C, Watanabe N, Chiba T. Pepsinogen C gene product is a possible growth factor during gastric mucosal healing. Biochem Biophys Res Commun 1997;238:17-20.
85. Fiorucci S, Santucci L, Gresele P, Luinetti O, Morelli A. Effect of NSAIDs on pepsinogen secretion and calcium mobilization in isolated chief cells. Am J Physiol 1995;268:G968-78.
86. Koch M, Dezi A, Ferrario F, Capurso L. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. Arch Intern Med 1996; 156:2321-32.
87. Lancaster C. Effective nonsteroidal anti-inflammatory drugs devoid of gastrointestinal side effects: do they really exist? Dig Dis 1995. 13 Suppl 1:40-7.
88. Laine L, Cominelli F, Sloane R, Casini-Raggi V, Marin-Sorensen M, Weinstein WM. Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double-blind trial. Aliment Pharmacol Ther 1995;9: 127-135.
89. Simon LS. Biologic effects of nonsteroidal antiinflammatory drugs. Curr Opin Rheumatol 1997;9: 178-82.
90. Nagase K, Hiwatashi N, Ito K, Maekawa H, Noguchi M, Kinouchi Y, Toyota T. Effects of NSAIDs and PGE1 analogue on the permeability of human small intestine. Nippon Shokakibyo Gakkai Zasshi 1997;94: 469-74.
91. Sontag SJ, Schnell TG, Budiman-Mak E, Adelman K, Fleischman R, Cohen S, Roth SH, Ipe D, Schwartz KE. Healing of NSAID-induced gastric ulcers with a synthetic prostaglandin analog (enprostil). Am J Gastroenterol 1994;89:1014-20.
92. Dajani EZ, Agrawal NM. Prevention of nonsteroidal anti-inflammatory drug-induced gastroduodenal ulcers: role of mucosal protective and gastric antisecretory drugs. Dig Dis 1995;13 Suppl 1:48-61.
93. Furst DE. Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum 1997;26: 21-7.
94. Ford-Hutchinson AW, Tagari P, Ching SV, Anderson CA, Coleman JB, Peter CP. Chronic leukotriene inhibition in the rat fails to modify the toxicological effects of a cyclooxygenase inhibitor. Can J Physiol Pharmacol 1993;71:806-10.
95. Kapui Z, Boer K, Rozsa I, Blasko G, Hermecz I. Investigations of indomethacin-induced gastric ulcer in rats. Arzneimittelforschung 1993;43:767-71.
96. Vaananen PM, Keenan CM, Grisham MB, Wallace JL. Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. Inflammation 1992;16:227-40.
97. Artenden DC, Ritchie DM, Ferro MP, Kirchner T, Wachter MP, Anderson DW, Rosenthale ME, Capetola RJ. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. J Pharmacol Exp Ther 1994;27:1399-409.
98. Weisman SM, Doyle MJ, Wehmeyer KR, Hynd BA, Eichhold TH, Clear RM, Coggeshall CW, Kuhlenbeck DL. Effects of tebufelone (NE-11740), a new anti-inflammatory drug, on arachidonic acid metabolism. Agents Actions 1994;41:156-63.
99. Depre M, Van Hecken A, Verbesselt R, Verpooten GA, Arnout J, Brunner F, Jurgens A, Pousset V, Chow A, Baldauf C, Vermylen J, De Broe M, De Schepper PJ. Biochemical activity, pharmacokinetics and tolerability of tepoxalin, a cyclooxygenase/5-lipoxygenase inhibitor, in man. Int J Clin Pharmacol Res 1996;16:1-8.
100. Bjarnason I, Macpherson A, Rotman H, Schupp J, Hayllar J. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen. Scand J Gastroenterol 1997;32:126-30.
101. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered aspirin. Lancet 1996;348:1413-6.
102. Caldwell JR, Roth SH. A double blind study comparing the efficacy and safety of enteric coated naproxen to naproxen in the management of NSAID intolerant patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 1994;21:689-95.
103. Lau CS, Morley KD, Belch JJ. Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis-a double-blind placebo controlled study. Br J Rheumatol 1993;32:982-9.
104. Tamblyn RM, McLeod PJ, Abrahamowisz M, Laprise R. Do too many cooks spoil the broth? Multiple physician involvement in medical management of elderly patients and potentially inappropriate drug combinations. Can Med J 1996;154:1177-84.
105. Tamblyn R, Berkson L, Dauphine WD, Gayton D, Grad R, Huang A, Isaac L, McLeod P, Snell L. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Intern Med 1997;127:429-38.
106. Satav JG, Bhattacharya RK. Respiratory functions in kidney mitochondria following paracetamol administration to young-adult and old rats. Ind J Med Res 1997;105:131-5.
107. Correa P, Schmidt BA. The relationship between gastric cancer frequency and the ratio of gastric to duodenal ulcer. Aliment Pharmacol Ther 1995;9 Suppl 2:13-19.
108. Ohtaka Y, Azuma T, Konishi J, Ito S, Kuriyama. Association between genetic polymorphism of the pepsinogen C gene and gastric body ulcer: the genetic predisposition is not associated with Helicobacter pylori infection. Gut 1997;41:469-74.
109. Kasugai K, Joh T, Kataoka H, Sasaki M, Tada T, Asai K, Kato T, Itoh M. Evidence for participation of gliostatin/platelet-derived endothelial cell growth factor in gastric ulcer healing. Life Sci 1997;61:1899-906.
110. Smedley FH, Taube M, Leach R, Wastell C. Nonsteroidal anti-inflammatory drug ingestion: retrospective study of 272 bleeding or perforated peptic ulcers. Postgrad Med J 1989;65:892-5.
111. Hayllar J, Bjarnason I. NSAIDs, Cox-2 inhibitors, and the gut. Lancet 1995;346:521-2.